Theravance Biopharma: Four holders report 0 shares

The reporting persons stated they did not effect transactions in TBPH shares during the past 60 days.

Rhea-AI Filing Summary

Theravance Biopharma, Inc. (TBPH) ownership amendment reports zero beneficial ownership for Weiss Asset Management, BIP GP LLC, WAM GP LLC, and Andrew M. Weiss, each at 0.0% of the class. It states that BIP and BGO each held zero shares, and that the reporting persons did not effect transactions in the issuer’s shares during the past 60 days.

The percentages were calculated using the issuer’s 51,918,754 shares issued and outstanding as of July 31, 2026. The statement says the issuer’s shares were cancelled on September 23, 2026, in connection with completion of its merger with Zymeworks Inc. The reporting persons disclaim beneficial ownership except to the extent of their pecuniary interests.

Key Figures

Reported beneficial ownership: 0 shares Reported ownership percentage: 0.0% BIP shares held: 0 shares +2 more

5 metrics

Reported beneficial ownership 0 shares Each of the four reporting persons

Reported ownership percentage 0.0% Each of the four reporting persons

BIP shares held 0 shares Item 5(a)

BGO shares held 0 shares Item 5(a)

Issuer shares issued and outstanding 51,918,754 shares As of July 31, 2026; used to calculate reported percentages

Key Terms

beneficial ownership, pecuniary interest, dispositive power

3 terms

beneficial ownership financial

"disclaims beneficial ownership of all of the Shares"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"except to the extent of its or his pecuniary interest therein"

dispositive power financial

"Sole Dispositive Power"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TBPH shares did the reporting persons beneficially own?

Each of the four reporting persons reported 0 shares, representing 0.0% of the class.

When were TBPH shares cancelled in connection with the Zymeworks merger?

The issuer’s shares were cancelled on September 23, 2026, in connection with completion of its merger with Zymeworks Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/25/2026 - 04:17 PM Accepted by SEC EDGAR 09/25/2026 - 04:01 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 4)

Theravance Biopharma, Inc.

(Name of Issuer)

Ordinary Share $0.00001 Par Value

(Title of Class of Securities)

G8807B106

(CUSIP Number)

Weiss Asset Management LP
c/o Georgiy Nikitin, 222 Berkeley St., 16th Floor
Boston, MA, 02116
(617) 778-7725

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

09/23/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): G8807B106

1

Name of reporting person

Weiss Asset Management LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

IA, PN

Comment for Type of Reporting Person:

Row 8, 10, 11, and 13: Please See Item 5

SCHEDULE 13D

CUSIP Number(s): G8807B106

1

Name of reporting person

BIP GP LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

HC, OO

Comment for Type of Reporting Person:

Row 8, 10, 11, and 13: Please See Item 5

SCHEDULE 13D

CUSIP Number(s): G8807B106

1

Name of reporting person

WAM GP LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

HC, OO

Comment for Type of Reporting Person:

Row 8, 10, 11, and 13: Please See Item 5

SCHEDULE 13D

CUSIP Number(s): G8807B106

1

Name of reporting person

Andrew M. Weiss

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

HC, IN

Comment for Type of Reporting Person:

Row 8, 10, 11, and 13: Please See Item 5

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Ordinary Share $0.00001 Par Value
(b)	Name of Issuer: Theravance Biopharma, Inc.
(c)	Address of Issuer's Principal Executive Offices: Ugland House, South Church Street, George Town, CAYMAN ISLANDS , KY1-1104.
Item 1 Comment: This Amendment No. 4 (this "Amendment") to Schedule 13D amends the Schedule 13D initially filed on April 12, 2023, (as amended prior to the date hereof, the "Prior Schedule 13D" and, as so amended by this Amendment, the "Schedule 13D") with respect to the items set forth below. Capitalized terms used without definition in this Amendment have the meanings assigned to them in the Prior Schedule 13D.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows: The percentages set forth above have been calculated based on 51,918,754 shares of the Issuer's Shares issued and outstanding as of July 31, 2026, as reported in the Issuer's Form 8-K, filed with the SEC on September 18, 2026. Each of the Reporting Persons disclaims beneficial ownership of all of the Shares, except to the extent of its or his pecuniary interest therein, and the filing of this Schedule 13D/A shall not be deemed an admission of beneficial ownership of any Shares for any purpose. 0 Shares, representing 0.0% of the outstanding shares of the Issuer, are held by BIP. BIP GP LLC is the general partner of BIP. Weiss Asset Management LP is the investment manager of BIP. Dr. Weiss is the managing member of WAM GP LLC and in such capacity has the power to vote and dispose of such Shares. 0 Shares, representing 0.0% of the outstanding shares of the Issuer, are held by BGO. Weiss Asset Management LP is the investment manager of BGO. Dr. Weiss is the managing member of WAM GP LLC and in such capacity has the power to vote and dispose of such Shares. See cover page above for the aggregate number and percentage beneficially owned by each of the Reporting Persons.
(b)	See Item 5 (a).
(c)	The Reporting Persons did not effect any transactions in the Issuer's Shares during the past 60 days. The Issuer's Shares were cancelled on September 23, 2026 in connection with the completion of the merger with Zymeworks Inc.
(d)	Other than the Funds that directly hold the securities of the Issuer, and except as set forth in this Item 5, no other person is known to have the right to receive, or the power to direct the receipt of, dividends from or proceeds from the sale, of the Shares.
(e)	September 23, 2026

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Weiss Asset Management LP

Signature:	Georgiy Nikitin
Name/Title:	GEORGIY NIKITIN, CHIEF COMPLIANCE OFFICER
Date:	09/25/2026

BIP GP LLC

Signature:	Georgiy Nikitin
Name/Title:	GEORGIY NIKITIN, CHIEF COMPLIANCE OFFICER
Date:	09/25/2026

WAM GP LLC

Signature:	Georgiy Nikitin
Name/Title:	GEORGIY NIKITIN, CHIEF COMPLIANCE OFFICER
Date:	09/25/2026

Andrew M. Weiss

Signature:	Georgiy Nikitin
Name/Title:	GEORGIY NIKITIN, ATTORNEY-IN-FACT FOR ANDREW M. WEISS**
Date:	09/25/2026

Comments accompanying signature:

** Duly authorized under Power of Attorney incorporated herein by reference to the exhibit to the Form 13G/A filed by Weiss Asset Management LP on January 25, 2017 in respect of its holding in Quinpario Acquisition Corp. 2.